Tsukioka K, Suzuki J, Kawauchi M, Wada Y, Zhang T, Nishio A, Koide N, Endoh M, Takayama K, Takamoto S, Isobe M, Amano J
Second Department of Surgery, Shinshu University, School of Medicine, Nagano, Japan.
J Heart Lung Transplant. 2000 Dec;19(12):1193-8. doi: 10.1016/s1053-2498(00)00188-1.
The mechanisms of intimal thickening in cardiac allograft vasculopathy (CAV) remain controversial after heart transplantation. Matrix metalloproteinase-2 (MMP-2) plays a crucial role in degrading extracellular matrix (ECM) during neointimal formation. Recently, it has been revealed that MMP-2 is activated by membrane-type 1 matrix metalloproteinase (MT1-MMP). This process involves tissue inhibitor of MMP-2 (TIMP-2), forming an MT1-MMP/TIMP-2/pro-MMP-2 complex. In this study, we hypothesize that these components contribute to the pathogenesis of CAV.
Heterotopic cardiac allografting was performed in randomly paired Japanese monkeys with an immunosuppressive regimen of intravenous administration of antihuman CD18 monoclonal antibody. The donor hearts were harvested at Days 22, 28, 40, 41, and 95 posttransplantation. We examined expression of MMP-2, MT1-MMP, and TIMP-2 of graft vessels using immunohistochemistry and protein level by western blot analysis.
Pathologically, various degrees of neointimal formation were observed. In the allografts harvested at Days 22, 28, 40, and 41, MT1-MMP was expressed in the endothelial cells and smooth muscle cells (SMCs) in media of some arteries without histological change, accompanied by expression of MMP-2 and TIMP-2. In the severely thickened neointima of the allograft harvested at Day 95, MMP-2 and faint MT1-MMP were expressed in SMCs of severely thickened neointima and media; TIMP-2 expression was seen only in noncollagenous tissue of severely thickened neointima. MMP-2 protein was more intensely expressed in the allograft harvested at Day 95 than in the allograft harvest at Day 41, while TIMP-2 protein level was almost same in the 2 samples.
We observed the simultaneous expression of MMP-2, MT1-MMP, and TIMP-2. Thus, ECM degradation triggered by MT1-MMP/TIMP-2/pro-MMP-2 complex could be a novel mechanism of CAV.
心脏移植后,心脏移植血管病变(CAV)中内膜增厚的机制仍存在争议。基质金属蛋白酶-2(MMP-2)在新生内膜形成过程中对细胞外基质(ECM)的降解起关键作用。最近,有研究表明MMP-2由膜型1基质金属蛋白酶(MT1-MMP)激活。这一过程涉及MMP-2的组织抑制剂(TIMP-2),形成MT1-MMP/TIMP-2/前MMP-2复合物。在本研究中,我们假设这些成分参与了CAV的发病机制。
对随机配对的日本猕猴进行异位心脏移植,并采用静脉注射抗人CD18单克隆抗体的免疫抑制方案。在移植后第22、28、40、41和95天采集供体心脏。我们通过免疫组织化学检测移植血管中MMP-2、MT1-MMP和TIMP-2的表达,并通过蛋白质印迹分析检测蛋白质水平。
病理检查发现不同程度的新生内膜形成。在移植后第22、28、40和41天采集的同种异体移植物中,一些动脉中层的内皮细胞和平滑肌细胞(SMC)表达MT1-MMP,且无组织学变化,同时伴有MMP-2和TIMP-2的表达。在移植后第95天采集的同种异体移植物严重增厚的新生内膜中,严重增厚的新生内膜和中层的SMC中表达MMP-2和微弱的MT1-MMP;TIMP-2仅在严重增厚的新生内膜的非胶原组织中表达。与移植后第41天采集的同种异体移植物相比,移植后第95天采集的同种异体移植物中MMP-2蛋白表达更强,而这两个样本中TIMP-2蛋白水平几乎相同。
我们观察到MMP-2、MT1-MMP和TIMP-2同时表达。因此,由MT1-MMP/TIMP-2/前MMP-2复合物触发的ECM降解可能是CAV的一种新机制。